BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company, today announced that poster presentations related to the Phase 3 Rejoice Trial of TX-004HR, the Company’s investigational, applicator-free vaginal estradiol softgel capsule for the treatment of moderate to severe dyspareunia (vaginal pain during sexual intercourse), a symptom of vulvar and vaginal atrophy (VVA) due to menopause, will be made at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting 2016, taking place in Charleston, South Carolina on February 25-28.
